Summary:

- The article discusses Epygen, an Indian biopharmaceutical company, and its focus on developing biosimilars, which are biological products that are highly similar to already approved biological drugs.
- Epygen has a pipeline of biosimilar candidates targeting various therapeutic areas, including oncology, immunology, and metabolic disorders, and is aiming to capitalize on the growing demand for affordable biological treatments.
- The article highlights Epygen's strategy of leveraging its in-house R&D capabilities, manufacturing expertise, and regulatory experience to develop and commercialize its biosimilar products, both in India and globally.